GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » ROIC %

NeuroPace (NeuroPace) ROIC % : -74.29% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroPace ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. NeuroPace's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -74.29%.

As of today (2024-05-11), NeuroPace's WACC % is 15.85%. NeuroPace's ROIC % is -96.74% (calculated using TTM income statement data). NeuroPace earns returns that do not match up to its cost of capital. It will destroy value as it grows.


NeuroPace ROIC % Historical Data

The historical data trend for NeuroPace's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace ROIC % Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-32.10 -32.79 -235.58 -224.74 -99.14

NeuroPace Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -147.50 -115.98 -106.64 -85.95 -74.29

Competitive Comparison of NeuroPace's ROIC %

For the Medical Devices subindustry, NeuroPace's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroPace's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's ROIC % distribution charts can be found below:

* The bar in red indicates where NeuroPace's ROIC % falls into.



NeuroPace ROIC % Calculation

NeuroPace's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-27.174 * ( 1 - 0% )/( (27.136 + 27.685)/ 2 )
=-27.174/27.4105
=-99.14 %

where

NeuroPace's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-20.204 * ( 1 - 0% )/( (26.709 + 27.685)/ 2 )
=-20.204/27.197
=-74.29 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroPace  (NAS:NPCE) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, NeuroPace's WACC % is 15.85%. NeuroPace's ROIC % is -96.74% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


NeuroPace ROIC % Related Terms

Thank you for viewing the detailed overview of NeuroPace's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroPace (NeuroPace) Business Description

Traded in Other Exchanges
N/A
Address
455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Executives
Martha Morrell officer: Chief Medical officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd. 10 percent owner CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker director, officer: Chief Executive Officer ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley officer: General Counsel and Secretary C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade director 6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield director C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer director 9701 JERONIMO, IRVINE CA 92618
Evan Norton director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob director 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet director, officer: Chief Executive Officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043